Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...
Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...
The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...
Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in ...
Triple-negative breast cancer is a fast-moving form of breast cancer that’s more common in younger women and harder to treat ...
New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early ...
October is Breast Cancer Awareness Month Having a family history that spanned four generations of breast cancer survivors, ...
After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback